Work Package 7: Implementation research to improve the existing screening programmes

WP 7

research transp

Implementation

Spain t

ICO, Spain

The overall objective is to provide tools and recommendations and reach consensus on essential processes to close the gap between current knowledge and practice in population-based cancer screening programmes (breast, colorectal, and cervical cancers), already provided as part of the standard services in most EU countries. Specific objectives are as follows:
1) To identify the level of implementation of quality assurance (QA) management systems in EU cancer screening programmes and provide guidance for implementing PROMS as a quality indicator;
2) To establish and standardise key definitions for measurement and reporting of interval cancer rates;
3) To evaluate the impact of integrating AI solutions into the workflow for breast, colorectal, and cervical cancer screening on diagnostic accuracy, workflow efficiency, and patient outcomes;
4) To identify the most effective invitation strategies that incorporate modern information technologies applied in population-based cancer screening programmes and provide recommendations applicable in different settings;
5) To develop a framework to support the piloting and implementation of self-sampling in cervical cancer screening;
6) To identify high-quality online decision aids for cancer screening (breast, colorectal, and cervical cancer) with proven efficacy in real-world settings and develop a web-based decision aid mock-up to facilitate informed decision-making in CRC screening.

Activities and division of work (WP description)

Task NrTask NameDescriptionParticipantsRoleIn-kind Contributions/Subcontracting
T7.1Implementing quality
assurance (QA) scheme
1.Situational analysis of quality management system implementation in
EU population-based cancer screening programmes, which entails a
stakeholder survey to identify EU population-based screening
programmes, assessment of the extent of quality management system
implementation, and determining number of countries with certification.
2. Identifying necessary resources for QA system implementation in
established cancer screening programmes, which entails interviews
with stakeholders involved in certified population-based screening
programmes to delineate the required resources.
3. Identifying steps necessary for implementing PROMs in cancer
screening programmes, which entails a systematic review to
understand the nuances and challenges of integrating PROMS into
cancer screening units, and a survey of EU MS that have successfully
implemented them. We will also develop a robust and adaptable
framework for their implementation across EU.
This task will be led by UCY, Cyprus, co-led by ICO, Spain.
LU
ICO, OIL, GÖG,
CIPH, MoH SK,
UCY, NIJZ, CPO,
IU NAMSU, NCI,
NOI, BCR
COO
BEN
AE
No
T7.2Classification and reporting
of interval cancer rates
Summarizing current variations in measurement of interval cancers
rate and the potential differences in screening programmes, we will
agree on definitions, calculation methodology and benchmark for
interval cancer rate. Further, we will pilot data collection; produce
report detailing purpose, methodology including international
comparison, and develop mechanism for ongoing data collection and
benchmarking.
This task will be led by HSE, Ireland, co-led by UCY, Cyprus
LU
DoH IE, OIL, ICO,
PHC, SCI,
UCY, NCI, BCR,
IU NAMSU, FHF
COO
BEN
AE
No
T7.3Integration of artificial
intelligence in cancer
screening programmes
1. Through a series of online workshops involving some of the leading
clinicians using AI in breast cancer screening practice and observing
best practice, we will collect experiences and create a knowledge base
on how AI influence the clinical practice.
2. Through user engagement, the knowledge base will be used to
create guidelines and practical tools supporting easier validation and
implementation of AI in breast cancer screening across Europe,
created and tested as part of the training in WP11.
3. Based on the insights from the above tasks and work on the MAS-AI
model in WP4 and WP10, a set of recommendations will be developed
to address the effect and accuracy of AI solutions (a) for improved
patient outcomes and support for decision makers regarding
acquisition of commercial solutions and (b) for breast cancer screening
and how they can be utilized in cervical and colorectal screening.
This task will be led by RSYD, Denmark.
RSYD
CSF, IACS,
RUMC, RCC,
OUS
BEN
AE
No
T7.4Innovative approaches to
invite target population in
cancer screening
programmes
1. Overview of different invitation strategies and the use of modern
information technology currently applied across EU and a review on
the evidence of their effectiveness in improving participation to
screening. We will draft a set of evidence-based recommendations on
implementing invitation practices that consider differences in the
organization of cancer screening.
2. Development of a framework for implementing self-sampling into
cervical cancer screening programs for different settings. This includes
a research protocol for piloting self-sampling that improves that can be
used when conducting pilot studies.
This task will be led by CSF (Finland).
LU
ICO, OIL, ISPRO,
PHC, NIHD
CSF, LSMUKK,
VULSK, AUSLRE,
IU NAMSU,
NNGYK
COO
BEN
AE
No
T7.5Implementing informed
decision-making in
population-based cancer
screening programmes
Online decision aids (DA) for breast, colorectal and cervical cancer
screening will be identified and their quality will be evaluated to
DAs with the best scores. Previous web-based DAs methods will be
identified and applied for development and testing, for instance, in
terms of detail compatibilities, characteristics, technical issues, search
term options, and factors to consider from the point of view of
technicians. DA contents will be identification and developed. An initial
version will be displayed in the web-based DA for CRC (FIT-based)
screening.
This task will be led by ICO, Spain.
LU
ICO, GÖG
IRFMN, DYPEDE
COO
BEN
AE
No

EUCanScreenLogo t

The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.

FaceBook
Twitter

Instagram

YouTube

LinkedIn

HaDEA EC

This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959

Print Friendly, PDF & Email
Μετάβαση στο περιεχόμενο